Acompanhe as Notícias da Recifes

Canadian Prime Minister Mark Carney said Tuesday he was looking at "all options" after US President Donald Trump made plans to impose new 50 percent tariffs on many Canadian goods in 30 days. Carney also said that he and Trump had agreed to "intensify discussions" in the coming w

NASA researchers recently put a new wing design, appearing long and thin with a lightweight structural design, through a series of grueling tests to find its structural limits. What they found left them encouraged about the wing’s potential, even when they pushed it past its inte

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.

Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy—including a near doubling of p

In "Evaluating the Evidence Base for New Mental Health Tech With APA Labs," JMIR correspondent Simon Spichak speaks with Tanya Carlson, MBA, managing director of APA (American Psychological Association) Labs, on how a new initiative—the Digital Badge Program—is helping developers

Researchers are sounding the alarm on the long-term impact of caring for children with developmental disabilities in the absence of proper societal supports across the life course. A new conceptual study, published in the Journal of Family Theory & Review, proposes a new model fo

New clinical data from the STEM-PD Phase I/II clinical trial have been presented at the ISSCR 2026 Annual Meeting. The study reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells for the

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented at the ISSCR 2026 Annual Meeting. The Phase Ib/IIa REGEN4HD study represents a significant translational milestone following years of p

New research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells